Comparative Mid-term Outcomes of Pediatric Hematogenous Methicillin-resistant Staphylococcus aureus and Methicillin-susceptible Staphylococcus aureus osteomyelitis

Abstract

The bacteria staphylococcus aureus is the most common etiology of acute hematogenous osteomyelitis (AHO) in healthy pediatric patients, accounting for 70-90% of cases. • AHO occurs at a rate of 1/10,000 pediatric patients/year. • Increasing prevalence of community-acquired methicillin resistant staph aureus (MRSA) is leading to a concurrent rise of such invasive pediatric infections in the US. • MRSA AHO on average have longer hospital stays, more febrile days, longer antibiotic therapy, and increase in overall complications vs. methicillin sensitive staph aureus (MSSA). • There is a lack of data on the functional outcome of these patients beyond 2 years post index infection. • Goal of study: compare treatment and midterm (2 years post index infection) functional outcomes between patients with MRSA vs. MSSA infections, and localized vs. disseminated infections. • Hypothesis: treatment and outcomes between MRSA and MSSA, and localized and disseminated, will be different, specifically that MRSA and disseminated will have worse midterm functional outcomes